Fierce Biotech May 17, 2024
On the heels of a groundbreaking FDA approval for a major medtech, a Silicon Valley startup is shaping up to be a possible competitor.
R3 Vascular recently raised $87 million in venture capital cash to support work on its bioresorbable, drug-eluting stent designed for peripheral artery disease—in addition to tapping a new president and CEO.
The company said the proceeds would support its pivotal clinical trial in patients with severe vessel blockages below the knee, including people facing the potential loss of the limb, as well as help scale up its manufacturing base.
Going forward, R3 Vascular will be led by Christopher Owens, who previously served as chief of the intrauterine fibroid ablation developer Gynesonics—and also formerly led IDEV...
Today's Sponsors
Today's Sponsor